Practice Areas

Education

University of North Carolina School of Law, J.D., 2007

University of Massachusetts at Amherst, B.A., Economics, magna cum laude, 2003
Phi Beta Kappa

Find Professionals
Photo of Joshua M. Diver

Joshua M. Diver

Associate
  • 150 Fayetteville Street, Suite 2300
    Raleigh, North Carolina 27601
  • Phone: 919.821.6731
  • Fax: 919.821.6800

Joshua Diver focuses his practice on representing public and private companies in mergers and acquisitions, venture capital financings, asset purchases and dispositions, joint ventures and stock offerings. Josh works with businesses both large and small, from start-up and growth companies to large public companies, and in a variety of industries, including life sciences, technology, financial services and manufacturing. In addition to his transactional work, Josh is an experienced advisor to public companies and investors concerning securities laws and corporate governance matters, including Sarbanes-Oxley, fiduciary duties, defensive takeover protections and strategies, 1934 Act compliance and disclosure matters, shareholder proposals, and proxy contests.

Prior to joining Smith Anderson, Josh practiced corporate law with Goodwin Procter LLP in Boston.

Professional & Community Affiliations

  • North Carolina Bar Association
  • Wake County Bar Association
  • African Leadership Foundation Host Family
  • Citizens Schools, Writing Coach

Honors & Awards

  • Note & Comment Editor, North Carolina Journal of International Law & Commercial Regulation
  • Recipient, Gressman-Pollitt Award for Best Appellant in Oral Argument
  • Member, Holderness National Moot Court Team

Experience

  • Represented a publicly traded company and leading provider of end-to-end spend management solutions in its sale of the company to a leading technology-focused private equity firm for approximately $509 million.
  • Represented the world’s largest public company provider of biopharmaceutical development services and commercial outsourcing services in connection with its joint venture with the world’s leading public company provider of diagnostic information services to form a global clinical trials laboratory services business with annual revenues of approximately $575 million.
  • Represented a publicly-traded and leading provider of end-to-end spend management solutions in its acquisition by a leading technology-focused private equity firm.
  • Represented a public medical device company in its $500 million acquisition of a product line from a public industrial company.
  • Represented a public bank holding company in its $233 million acquisition of another public bank holding company.
  • Represented European bank in a $900 million sale of asset-based lending business to U.S. based bank.
  • Represented public clean energy company in a strategic alliance with a European multinational energy company.
  • Represented a closely-held chemical manufacturing company in its sale to a European multinational chemical manufacturing company.
  • Represented a public technology company in its $50 million acquisition of another public technology company.
  • Represented a public medical device company in its $38 million acquisition of assets from private medical device company.
  • Represented a test preparation services company in its acquisition of a test preparation software company.
  • Represented a public bank holding company in its joint venture with a public payment processing company.
  • Represented private equity fund in its acquisition of a savings and loan association.
  • Represented public bank holding company it its $10 million sale of a private trust company to another public bank holding company.
  • Represented a public banking holding company in its $62 million acquisition of another public bank holding company.
  • Represented a public banking holding company in its $93 million sale of bank subsidiary in connection with management-led buyout.
  • Represented medical services company in a bolt-on acquisition.
  • Represented a private equity fund in its purchase of stock issued by late-stage private technology company.
  • Represented public life sciences company in private placement of common stock and warrants.
  • Represented public life sciences company in registered direct offering of common stock and warrants.
  • Represented numerous private companies in venture financing transactions.